Abstract: Human and bovine bone inductive factors are provided. Such factors may be produced by recombinant techniques and be useful in the treatment of bone defects.

Abstract: Novel procoagulant proteins are disclosed which comprise the amino acid sequence:A-X-Bwherein region A represents the polypeptide sequence Ala-20 through Arg-759 substantially as shown in Table 1; region B represents the polypeptide sequence Ser-1709 through Tyr-2351 substantially as shown in Table 1; and region X represents a polypeptide sequence comprising up to 949 amino acids substantially duplicative of sequences of amino acids within the sequence SER-760 through Arg-1708 of Table 1, wherein the amino terminus of X is covalently bonded through a peptide bond designated "-" to the carboxy terminus of A, and the carboxy terminus of X is likewise bonded to the amino terminus of B. Methods of making such proteins and their use in pharmaceutical preparations is also disclosed.

Abstract: A novel family of primate CSF-1-like polypeptides is provided via recombinant techniques.

Abstract: A storage stable single phase aqueous composition is provided which is useful in isolatin nucleic acids from cell or virus cultures.

Abstract: A new improved glycoprotein having erythropoietin-type activity is disclosed. The substrate is characterized by amino acid sequence substantially identical to the amino acid sequence of native human erythropoietin wherein the methionine-54 is replaced with leucine. DNA encoding for the EPO-substance and expression vectors incorporating the same are disclosed. Therapeutic compositions and methods for treatment of anemic conditions are described.

Abstract: A method for isolating and purifying nucleic acids from eukaryotic and prokaryotic cell cultures or viral cell cultures.

Abstract: This invention relates to a process for producing a desired alpha-amino acid, AA.sub.d, or a derivative thereof. The process comprises:(a) reacting a first alpha-amino acid, AA.sub.NH.sbsb.2 ; a first alpha-keto acid, KA.sub.t ; a second alpha-keto acid, KA.sub.pre ; a first transaminase enzyme and a second transaminase enzyme to produce (i) the desired alpha-amino acid, AA.sub.d and (ii) a third alpha-keto acid, KA.sub.prod ; and(b) removing KA.sub.prod from the other keto acids, amino acids and enzymes wherein AA.sub.d and KA.sub.pre, AA.sub.t and KA.sub.t, and AA.sub.NH.sbsb.2 and KA.sub.prod are interconvertible, respectively, by amino group transfer. The first transaminase efficiently catalyzes reaction (i), but not reaction (ii) and the second transaminase efficiently catalyzes reaction (ii) but not reaction (i):AA.sub.NH.sbsb.2 +KA.sub.t .revreaction.AA.sub.t +KA.sub.prod (i)AA.sub.t +KA.sub.pre .revreaction.AA.sub.d +KA.sub.t (ii)In one embodiment KA.sub.

Abstract: This invention concerns a method for producing a heterologous protein in a bacterial host cell such that the protein is exported from the host cell into the culture medium. The method involves culturing in a bacterial culture medium a genetically engineered bacterial strain containing a fusion DNA sequence comprising a first nucleotide sequence encoding at least an N-terminal portion of a flagellin protein and a second nucleotide sequence encoding the heterologous protein. The first nucleotide sequence is linked via its 3' terminus to the 5' terminus of the second nucleotide sequence, and the fusion DNA sequence is itself linked to an expression control sequence.

Abstract: High yields of active Factor IX are produced by culturing a CHO cell line transfected with chromosomally-integrated Factor IX cDNA in medium to which vitamin K is added.

Abstract: The mRNA of a distinct human Interleukin-2 concentrated from a plasma source lead to the production and cloning of its cDNA and the elucidation of its sequence and that of the mature protein. Transfer vectors for production of such Interleukin-2 are disclosed along with useful intermediate expression products.

Abstract: A method for determining the presence and amount of a predetermined target nucleotide sequence in a biological sample is provided. The method employs a reagent complex which consists of a labeled probe polynucleotide having a target binding region and a second polynucleotide bound to the labeled probe in a second polynucleotide binding region thereof. The second binding region is at least partially coextensive with the target binding region. This reagent complex is contacted with a sample under conditions in which the target sequence binds to the labeled probe, displacing the second polynucleotide. Labeled probe/target hybrids are separated from intact reagent complexes and the presence and amount of these hybrids are determined.

Abstract: Eucaryotic cells cotransformed with product and selection genes yield considerably greater quantities of product after a novel subcloning strategy is employed: Transformants are identified for product yield, cultured under selection pressure and the progeny screened for product yield. Novel transformation vectors contain directly ligated selection and product genes and/or eucaryotic promoters.

Abstract: A method for purifying erythropoietin is described. The method comprises treating partially purifying erythropoietin by reverse phase high performance liquid chromatography to obtain homogeneous erythropoietin having a molecular weight of about 34,000 daltons on SDS PAGE and moving a single peak on reverse phase HPLC. The homogeneous erythropoietin protein preferably has a specific activity of at least 120,000 IU, more preferably at least 160,000 IU per absorbance unit at 280 nm.

Abstract: Disclosed are 2-(pyridinyl)-1,2,4-triazolo[1,5-a]pyrimidines and derivatives which are effective in increasing cardiac contractility. These compounds are useful in the treatment of congestive heart failure preferably by oral or parenteral administration.

Abstract: Stable pharmaceutical compositions comprising gentamicin and gleptoferron prevention of iron deficiency anemia and bacterial infections in young mammals, especially piglets.

Abstract: An elegant topical cream composition, containing betamethasone dipropionate, for the treatment of inflammation.

Abstract: Disclosed is an elegant formulation of betamethasone dipropionate useful as a topical anti-inflammatory product.

Abstract: Disclosed are triazolyl-substituted propane derivatives useful in the treatment of fungal diseases of humans and animals. Also disclosed are the processes for preparing the compounds, pharmaceutical compositions containing them, and the method of treating fungal diseases with said compounds.

Abstract: Disclosed is an elegant cream-like formulation of betamethasone dipropionate useful as a topical antiinflammatory product.